Shailendra Kumar Dhar Dwivedi
University of Oklahoma Health Sciences Center, Veer Bahadur Singh Purvanchal University, Deen Dayal Upadhyaya Gorakhpur University
Research areas: Medicine · Oncology · Ovarian cancer diagnosis and treatment · Epigenetics and DNA Methylation · Cancer Cells and Metastasis
0000-0002-5410-2032
About
I am a cancer biologist with over twelve years of experience investigating the molecular mechanisms underlying ovarian cancer progression and therapeutic resistance. My expertise spans cell signaling, non-coding RNA biology, redox regulation, and translational modeling. My research integrates molecular and preclinical approaches to uncover pathways that drive ovarian cancer progression and limit chemotherapy effectiveness. A major focus of my work has been elucidating the tumor-suppressive roles of microRNAs in regulating oncogenic signaling, metabolic adaptation, and chemoresistance. My earlier studies identified miR-15a, miR-16 and miR-195 as a critical suppressor of ovarian cancer proliferation, metastasis, and therapy resistance. More recently, my research has expanded to explore the interplay between long non-coding RNAs (lncRNAs) and microRNAs, particularly MIR497HG, the host gene for miR-195 and miR-497, in controlling tumor growth, stemness, and chemoresistance.
My current research aims to define the dual miRNA-dependent and miRNA-independent functions of MIR497HG and the mechanisms regulating its expression in high-grade serous ovarian cancer (HGSOC). Preliminary data indicate that loss of MIR497HG and its embedded miRNAs promotes tumor proliferation, metastasis, and resistance to therapy. Building on prior work, including the development of Auroliposomes for miR-195 delivery, this project combines mechanistic and translational strategies to restore MIR497HG expression, inhibit oncogenic networks, and enhance therapeutic response in HGSOC. In parallel, my ongoing research is deciphering the role of NNT-AS1 in NADPH-associated signaling and its contribution to ovarian cancer metastasis.
Since establishing my independent laboratory in 2023, I have built a strong research team, mentored trainees, and advanced multiple projects linking non-coding RNAs, mitochondrial metabolism, and ovarian cancer therapy resistance. My expertise in ovarian cancer biology, ncRNA regulation, and translational modeling uniquely positions me to lead this project. Through this work, my long-term goal is to develop effective therapeutic strategies that resensitize ovarian cancers to chemotherapy, improve patient outcomes, and reduce the burden of this lethal disease.
Employment
-
University of Oklahoma Health Sciences Center Assistant Professor2023 - Present
-
The University of Oklahoma Health Sciences Center Assistant Professor of Research2018 - 2023
-
University of Oklahoma Health Sciences Center Postdoctoral Research Fellow2013 - 2018
Education
-
Veer Bahadur Singh Purvanchal University Master of Science2002 - 2004
-
Deen Dayal Upadhyaya Gorakhpur University Bachelor of Science1998 - 2001
Projects & Funding
-
Investigating the Role of Tumor Microenvironment and Extracellular Vesicles in Uterine Carcinosarcoma OUHSC Stephenson Cancer Center2025 - 2026
-
Biomarkers and Therapeutic Targets in Uterine Carcinosarcoma: The Role of Extracellular Vesicles and the Tumor Microenvironment Oklahoma University Stephenson Cancer Center2025 - 2026
-
Role of miR-195 in Chemo-Resistant Ovarian Cancer National Cancer Institute2023 - 2023
-
miR-195 Re-Expression: A Therapeutic Strategy for Chemoresistant Ovarian Cancer Congressionally Directed Medical Research Programs2023 - 2027
Publications (51)
- Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. Save
- Enhancing mRNA therapy through iterative delivery Save
- Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding. Save
- Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer Save
- Uterine carcinosarcoma: Unraveling the role of epithelial‐to‐mesenchymal transition in progression and therapeutic potential Save
- Secrets of DNA-PKcs beyond DNA repair Save
- VEGF signaling: Role in angiogenesis and beyond Save
- A role for the cystathionine-β-synthase /H2S axis in astrocyte dysfunction in the aging brain Save
- The deubiquitinase USP10 protects pancreatic cancer cells from endoplasmic reticulum stress Save
- Targeting BMI1 mitigates chemoresistance in ovarian cancer Save
- Disabling partners in crime: Gold nanoparticles disrupt multicellular communications within the tumor microenvironment to inhibit ovarian tumor aggressiveness Save
- Small Non-Coding-RNA in Gynecological Malignancies Save
- Targeting the TGFβ pathway in uterine carcinosarcoma Save
- MicroRNA‐195 controls MICU1 expression and tumor growth in ovarian cancer Save
- Ubiquitin‐binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer Save
- Cystathione β-synthase regulates HIF-1α stability through persulfidation of PHD2 Save
- Cystathionine beta synthase regulates mitochondrial dynamics and function in endothelial cells Save
- KRCC1: A potential therapeutic target in ovarian cancer Save
- Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis Save
- Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer Save